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Risk-stratification of acute myeloid leukemia (AML) based on recurrent somatic
abnormalities has evolved substantially in recent years, as illustrated by the cur-
rent 2017 European LeukemiaNet (ELN) risk stratification.1 These 2017 ELN AML
risk stratification recommendations are based on (cyto)genetic aberrations, includ-
ing hotspot mutations such as those in NPM1, but also small insertions, deletions
and point mutations that occur throughout TP53, RUNX1 and ASXL1, the latter
being associated with adverse outcome.1 Next-generation sequencing (NGS)
enables reliable detection of patient-specific mutations covering complete genes in
molecularly heterogeneous diseases such as AML. NGS should, therefore, be
incorporated in the routine work-up of preferably bone marrow specimens for
accurate risk stratification in AML. Since risk assessment according to 2017 ELN
recommendations only requires knowledge of the status of a handful of well-
known driver mutations,1 targeted NGS, easily reaching a sensitivity of 1-2%, is
currently the most appropriate and cost-effective approach for routine testing in
AML. Targeted NGS using a variety of gene panels has been successfully intro-
duced in routine clinical laboratories; however, several challenges remain. 
Gene panels
A number of commercially available gene panels focusing on genes frequently
mutated in myeloid malignancies have been introduced, e.g., the Illumina TruSight
Myeloid panel, the Archer VariantPlex Core Myeloid panel, the Human Myeloid
Neoplasms QIASeq DNA Panel and the AmpliSeq for Illumina Myeloid panel
among many others. As expected, these panels contain all genes relevant for the
2017 ELN classification and show an enormous overlap in additional mutational
hotspots and complete coverage of genes frequently mutated in myeloid diseases.
In addition to these commercial panels, gene panels can be easily configured to
meet local requirements. For instance, if AML patients are classified locally accord-
ing to 2017 ELN, only NPM1, CEBPA, FLT3, RUNX1, ASXL1, and TP53 need to be
included in a small and cost-effective gene panel. These types of NGS-based assays
are now emerging.2 Importantly, both commercial NGS-based assays and those
developed in-house as well as downstream analyses should be thoroughly validat-
ed locally before implementation in daily practice can be considered.   
Some genes are particularly difficult to sequence with NGS using gene panels.
Bi-allelic mutations in CEBPA characteristically confer a favorable outcome in
patients with AML.1 CEBPA is a GC-rich gene which is notoriously difficult to
amplify by polymerase chain reaction (PCR) and sequence, and should be given
special attention when incorporated in a gene panel. Although some commercial
NGS gene panel protocols do now successfully include this single exon gene,
other NGS approaches, such as capture-based NGS or custom panels for CEBPA
mutation detection could be considered. FLT3 internal tandem duplications (ITD)
can be reliably determined by fragment-length PCR following standardized pro-
tocols;3 however, the size of the FLT3 ITD and the duplication itself make it chal-
lenging to sequence the variably-sized amplicons appropriately by NGS and sub-
sequently to analyze the FLT3 ITD by sequence alignment to reference sequences.
Moreover, the 2017 ELN recommendations require assessment of the size of the
FLT3 ITD clone.1 NPM1-mutant AML cases with high FLT3 ITD/FLT3 wildtype
ratios (>0.5) are considered at intermediate risk, whereas NPM1 wildtype AML
cases with high FLT3 ITD/FLT3 wildtype ratios are seen as adverse. Standardized
NGS-based protocols need to be developed not only for the detection of FLT3
ITD, but also for the quantification of FLT3 ITD/FLT3 wildtype ratios. Examples
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of sensitive and specific custom-made FLT3 ITD NGS-
based mutation detection assays have been published.4,5
Sequencing
A selected number of fusion transcripts have been
incorporated in the 2017 ELN recommendations and clas-
sify AML patients into various risk categories.1 Although
the majority of these gene rearrangements are revealed by
cytogenetic analyses, molecular approaches are often
complementary. Fusion transcript detection was long lim-
ited to those transcripts for which standardized assays,
generally real-time quantitative PCR, were available.
However, all fusion transcripts relevant for risk stratifica-
tion of AML can now be detected in a single assay with
RNA-based NGS (RNA sequencing). Given that at least
one of the partner genes involved in all clinically relevant
fusions is known, RNA sequencing analysis can focus on
these specific genes, leaving the possibility of revealing
novel fusion partners. Such targeted RNA sequencing-
based assays are commercially available. However, since
the number of clinically relevant fusion transcripts is lim-
ited, one could also consider developing customized
methods in which the AML-associated transcripts are
amplified by (multiplex) PCR and subsequently
sequenced by NGS.6 Again, proper validation of these
assays at the local site is essential.
Currently, library preparation and sequencing with
amplicon-based NGS assays usually require several days,
whereas analyses of the limited number of 2017 ELN
genes can be done rather quickly. The introduction of
novel NGS machines with faster turnaround times, such
as the Illumina iSeq100, and the development of cu -
stomized assays now enable fast library preparation and
overnight sequencing, thus allowing for a quick return of
test results to the clinic. This is of particular interest when
targetable mutations, such as those in FLT3, IDH1 or
IDH2, are needed for selection of the appropriate drug for
front-line AML therapy or for relapsed patients with a
high disease burden. 
Since most of the clinically relevant mutations in
myeloid malignancies are known, targeted sequencing is
currently the method of choice. However, it can be fore-
seen, when turnaround times and costs are reduced, that
whole exome or whole genome sequencing will become
the standard approach to genomic characterization of
AML at diagnosis. The use of whole exome or whole
genome sequencing will allow identification of all somat-
ic coding mutations, including those that are targetable
but less frequently present in AML. Moreover, one can
prioritize analysis of key AML genes first, such that initial
results regarding the clinically most relevant genes can be
obtained with a short turnaround and more comprehen-
sive genomic profiling can follow later. Furthermore,
whole genome sequencing allows identification of novel
biomarkers located outside of protein coding regions,
which may be useful not only for proper assessment of
the prognosis but also for detection of minimal residual
disease (MRD) in AML as they can be used to identify
and follow leukemic clones regardless of their role in
AML initiation and maintenance.
Minimal residual disease
Our improved understanding of the molecular land-
scape of AML has resulted in better treatment decisions at
the time of complete remission after induction treatment.
Although the majority of AML patients achieve complete
remission, many eventually relapse. Thus, there is still a
great need for adequate prediction for subsequent relapse
to adapt treatment accordingly and improve the out-
comes of patients at high risk of relapse. MRD detection
has already proven to have substantial value in predicting
relapse and overall survival when applied to AML in com-
plete remission but the use of molecular enumeration of
MRD has been limited to only specific, molecularly
defined subtypes of AML.7-9 By contrast, flow cytometric
analysis of MRD can be done in nearly all AML patients,
but is operator- and center-dependent and there is no cen-
trally agreed approach to enumerate flow-based MRD in
AML. NGS enables MRD detection by measuring all
mutations, including patient-specific persistent muta-
tions, in complete remission. In fact, it has recently been
shown that molecular MRD detection by NGS is applica-
ble to virtually every newly diagnosed AML patient
because of the frequent prevalence of multiple molecular
aberrations among patients with AML.10-13 However,
MRD detection based on NGS must overcome several
challenges before it can be reliably introduced into clini-
cal practice.
The known oligoclonality of the disease at diagnosis
has a clear impact on MRD detection. Molecular markers
in small AML subclones at diagnosis could easily be
missed by panel-based NGS at lower depth. However,
these small populations of cells may be selected during
therapy and ultimately result in AML relapse. This issue
could be overcome by sensitive detection of all possible
mutations frequently present in myeloid malignancies.
However, because of the relatively high error rates of
current standard NGS technologies, reliable detection of
a multitude of mutations at high sensitivities (<0.01%) is
not yet easily achieved. In fact, the currently high intrin-
sic error rates (1 to 0.1%) impede sensitive MRD moni-
toring at later time points during therapy as well. At
these time points certain targets present at diagnosis can
be sequenced individually with single amplicons at high
depth, but true residual mutations may still not be reli-
ably discriminated from noise at levels below 0.1%.
Attempts should be made to improve the signal-to-noise
ratios in order to detect low-level variants accurately.14
Genomic DNA isolated from bone marrow, peripheral
blood or mononuclear cells is generally of high quality,
but noise in NGS is subsequently introduced at different
levels during library preparation and sequencing.14 The
rate of sequencing artefacts can be reduced biochemical-
ly, e.g., by using proof-reading polymerases, or compu-
tationally; however, these corrections are only modest
and cannot attenuate errors/artefacts entirely.
Alternative strategies should be explored. Recently, vari-
ous error-corrected NGS methodologies using molecular
barcoding have been introduced.14 Error-corrected
sequencing is based on barcoding the individual DNA
molecules used for NGS library preparation. Using the
unique sequence tag all derivative reads, which arise
from a common founder, can be recognized after com-
putational NGS, which enables removal of PCR dupli-
cates and false mutation calls. These approaches and
protocols15 have been shown to increase the specificity
of low-frequency mutation detection.14 However,
whether error-corrected sequencing will improve MRD
detection by NGS in AML remains to be demonstrated
in large cohorts of AML.    
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Recently, several studies addressed NGS-based MRD
detection in relatively large AML cohorts from clinical tri-
als, all demonstrating that NGS-based MRD has a pro-
found prognostic impact in patients with AML.11-13,16 In
these studies persistent mutations in complete remission
were measured with gene panels,11 capture-based deep
sequencing10,12,16 or targeted sequencing.13 The amplicon-
based approach was specifically designed for MRD detec-
tion by including error-correction,13 which suggests that
previous NGS-based MRD studies were not yet optimal.
The results of these initial studies do not allow any firm
conclusions to be drawn with regard to the superiority of
error-corrected NGS for MRD detection in AML.
However, the fact that NGS MRD has consistent prog-
nostic value implies that technological improvements
should be made in order to further optimize relapse pre-
diction in AML, assuming that in these initial studies
minor AML MRD clones were missed in complete remis-
sion. The ELN MRD Working Group is currently aiming
to improve and harmonize methodologies for NGS-based
detection of MRD in AML. 
Another successful approach to correct for noise is to use
a site-specific error model with a sufficiently large set of
reference samples without mutations.11 In such a model the
distribution of variants is determined in a reference set
without mutations, for example, remission samples. MRD
is subsequently defined by those mutations, such as the
ones present at diagnosis, which are statistically signifi-
cantly different from the distribution of variants in the ref-
erence set. In this case the detection sensitivity of muta-
tions is variable and dependent on the average coverage for
that specific locus for all samples, the observed error vari-
ance of the site-specific variant in the reference set (a high
variance results in decreased detection sensitivity) and the
number of control samples available. A major drawback of
this approach is that a set of reference samples to deter-
mine MRD has to be available. MRD measurement in a
single sample without the dependence of a large reference
set is obviously a preferred method since it will be more
easily implemented in clinical practice.  
Clonal hematopoiesis
In the initial NGS-based MRD studies11-13,16 it became
clear that gene mutations persisting in complete remis-
sion that are well-known to be associated with clonal
hematopoiesis17,18 do not have an impact on the risk of
relapse, despite the fact that they are among the most
common disease-initiating drivers of AML. As a result of
high-dose chemotherapy, AML patients with these muta-
tions are apparently brought back into a state of clonal
hematopoiesis, in which mutations occurring late in
leukemogenesis are irradiated, but mutations also found
in clonal hematopoiesis persist. It is clear that these per-
sisting mutations, also known as clonal mutations of
indeterminate potential, add another layer of complexity
to MRD detection in AML.
In studies of molecular MRD, clonal hematopoiesis-
related mutations in DNMT3A, TET2 and ASXL1 (DTA)
were considered clonal hematopoiesis rather than resid-
ual leukemia. Besides acquired mutations in DTA, other
well-known pathogenic mutations such as those in TP53,
PPM1D, JAK2, CBL, SRSF2 and SF3B1 are involved in
clonal hematopoiesis, however, at lower incidence.17,18 In
fact, many of these mutations also persist in complete
remission with high variant allele frequencies. It needs to
be determined whether and, if so, to what extent persist-
ing mutations other than those in DTA represent true
residual leukemia or clonal hematopoiesis, respectively
with and without an increased risk of relapse. In a disease
as heterogeneous as AML these analyses will require
large cohorts of patients. Thus, while the recent develop-
ments in NGS-based MRD detection represent major
steps forward in predicting relapse, they remain imper-
fect. It is expected that a better distinction between clonal
hematopoiesis and residual leukemia will improve pre-
diction of AML patients at higher risk of relapse. 
How can the discrimination between true residual
leukemia and clonal populations of cells be improved?
The numbers of AML patients included in the initial stud-
ies precluded detailed analyses of rare mutations and in-
depth analysis of common non-DTA mutations. It is con-
ceivable that non-DTA mutations are a mixture of muta-
tions representative of either true leukemia or clonal
hematopoiesis. Improved discrimination of these two
conditions by means of types of persisting mutations may
have significant value with regards to relapse prediction.
Along the same lines it has recently been shown that it
may be feasible to discriminate clonal hematopoiesis
from pre-AML in healthy individuals.19 Pre-AML cases
were distinct from controls and had more mutations per
sample, higher variant allele frequencies, indicating clonal
expansion, and showed enrichment in specific genes.19
Similar approaches could possibly better differentiate
clonal hematopoiesis from true leukemia after induction
treatment. 
Sensitivity, timing and tissues for next-generation
sequencing 
How does NGS-based MRD detection perform as com-
pared to the ‘golden standard’, multiparameter flow cyto-
metric MRD detection? There are only limited studies
with a rigorous comparison between NGS- and multipa-
rameter flow cytometric MRD detection.11,16 These stud-
ies demonstrate that there is a 70% concordance with
regard to MRD detection using the two technologies, and
that those patients who are MRD-positive according to
both techniques have the highest risk of developing an
AML relapse.11,16 Interestingly, however, those AML cases
with discordant results from NGS and flow cytometry
have adverse outcome, such that MRD positivity has
value whether determined by flow cytometry, molecular
techniques, or both.11,16 We need to improve both the sen-
sitivity of our NGS assays and our understanding of the
biology of clonal hematopoiesis after high-dose
chemotherapy to resolve the discordant cases and deter-
mine whether we require both technologies or only one
to enumerate MRD.   
At which time point(s) should NGS-based MRD detec-
tion be carried out? In the majority of AML studies NGS-
based MRD detection was performed after high-dose
induction treatment. Although this time point may be
most suitable for choosing the proper consolidation treat-
ment, it is not known whether MRD assessment at other
time points may be better prognostic indicators. Few
studies have shown that MRD before and after consolida-
tion, such as in the setting of allogenic transplantation,
affects clinical outcome.12,16,20
A bone marrow biopsy is an invasive procedure that
gives stress and physical discomfort to a patient and cre-
ates a risk of infection. Patients with chronic myeloid
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leukemia are monitored by measuring BCR-ABL1 levels
in peripheral blood. Likewise, in mutant NPM1 AML,
response to treatment can be effectively ascertained in
peripheral blood. Studies should be carried out to deter-
mine whether peripheral blood is also an alternative for
NGS-based MRD monitoring in AML for a broader spec-
trum of molecular alterations.
Conclusions
NGS at diagnosis is essential for accurate risk stratifica-
tion of AML patients according to the 2017 ELN recom-
mendations and has now been implemented in many
molecular diagnostic laboratories. Currently, the major
limitations of the NGS-based methodology of detecting
MRD are related to the limited sensitivity and specificity
of the assays and the inability to discriminate correctly
between residual leukemia and clonal hematopoiesis.
Improvements need to be made in these areas before
NGS-based MRD detection can be successfully imple-
mented in routine practice.
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